Market Place
Sourcing Support
Dr. Tom Zhang Presents At Immunogenicity & Bioassay Summit
16 Oct 2024 //
BUSINESSWIRE
AbbVie`s ovarian cancer therapy succeeds in mid-stage trial
07 Jun 2024 //
REUTERS
In less than 3 months, AbbVie closes $10.1B buyout of ImmunoGen
12 Feb 2024 //
FIERCE PHARMA
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2024 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jan 2024 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
BUSINESSWIRE
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
01 Dec 2023 //
REUTERS
ImmunoGen Announces Webcast of Presentation
02 Nov 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2023 //
BUSINESSWIRE
Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?
25 Oct 2023 //
FINANCE YAHOO
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Results
19 Oct 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Sep 2023 //
BUSINESSWIRE
ELAHERE Shows Progression-Free Survival Regardless of Prior PARPi Exposure
28 Sep 2023 //
BUSINESSWIRE
ImmunoGen Appoints Lauren White as Senior VP and Chief Financial Officer
18 Sep 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Sep 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2023 //
BUSINESSWIRE
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
31 Jul 2023 //
BUSINESSWIRE
ImmunoGen Announces Webcast of Presentation at Canaccord Genuity Conference
27 Jul 2023 //
BUSINESSWIRE
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Results
17 Jul 2023 //
BUSINESSWIRE
ImmunoGen Announces Closing of Public Offering and Full Exercise
09 May 2023 //
BUSINESSWIRE
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial
09 May 2023 //
BUSINESSWIRE
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
05 May 2023 //
CLINICAL TRIALS ARENA
Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales
28 Apr 2023 //
ENDPTS
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
28 Apr 2023 //
BUSINESSWIRE
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and CMO
24 Apr 2023 //
BUSINESSWIRE
ImmunoGen Announces Conference to Discuss First Quarter 2023 Operating Results
13 Apr 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2023 //
BUSINESSWIRE
ImmunoGen Presents Additional Efficacy Data from the SORAYA Trial
27 Mar 2023 //
BUSINESSWIRE
ImmunoGen Reports Recent Progress and 2022 Financial Results
01 Mar 2023 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2023 //
BUSINESSWIRE
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
22 Feb 2023 //
BUSINESSWIRE
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
15 Feb 2023 //
BUSINESSWIRE
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
01 Feb 2023 //
BUSINESSWIRE
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
29 Dec 2022 //
BUSINESSWIRE
ImmunoGen Announces Webcast of Presentation and Q&A at 41st Annual J.P. Morgan
27 Dec 2022 //
BUSINESSWIRE
Biosion Announces Collaboration with ImmunoGen to Create Antibody-Drug Conjugate
13 Dec 2022 //
PRNEWSWIRE
ImmunoGen Presents Findings from Cohorts in Phase 1b/2 of Pivekimab Sunirine
10 Dec 2022 //
BUSINESSWIRE
ImmunoGen Announces Collaboration with Gilead to Evaluate Pivekimab Sunirine
09 Dec 2022 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2022 //
BUSINESSWIRE
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
21 Nov 2022 //
BUSINESSWIRE
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients
18 Nov 2022 //
ACCESSWIRE
ImmunoGen gains FDA nod for advanced ovarian cancer drug Elahere
16 Nov 2022 //
FIERCEPHARMA
FDA grants accelerated approval for ImmunoGen’s ovarian cancer ADC
15 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
ImmunoGen Announces FDA Approval of ELAHERE for the Treatment of Ovarian Cancer
14 Nov 2022 //
BUSINESSWIRE
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
04 Nov 2022 //
BUSINESSWIRE
ImmunoGen Announces Departure of Chief Commercial Officer
01 Nov 2022 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2022 //
BUSINESSWIRE
ImmunoGen Announces Departure of CCO
01 Nov 2022 //
BUSINESSWIRE
ImmunoGen Announces Conference to Discuss Third Quarter 2022 Operating Results
20 Oct 2022 //
BUSINESSWIRE
ImmunoGen Presents Updates for Mirvetuximab Soravtansine Combination Data
29 Sep 2022 //
BUSINESSWIRE
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Conference
14 Sep 2022 //
BUSINESSWIRE
ImmunoGen Presents Analyses Evaluating Mirvetuximab Soravtansine
11 Sep 2022 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2022 //
BUSINESSWIRE
ImmunoGen pushes readout of rare blood cancer trial to 2024
31 Aug 2022 //
ENDPTS
ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024
31 Aug 2022 //
FIERCEBIOTECH
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine
31 Aug 2022 //
BUSINESSWIRE
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
BUSINESSWIRE
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
29 Jul 2022 //
BUSINESSWIRE
ImmunoGen Announces Conference Call to Discuss Q2 2022 Operating Results
14 Jul 2022 //
BUSINESSWIRE
